<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of the clinical presentation and diagnosis of acute lymphoblastic leukemia/lymphoma in children
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Terzah M Horton, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jon C Aster, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Julie R Park, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 08, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H625284778">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) is the most common childhood malignancy. The term ALL/LBL is used because the current system for diagnosis and classification does not distinguish between clinical presentations as leukemia or lymphoma [
         <a href="#rid1">
          1
         </a>
         ]; by convention, the term lymphoma is used when disease is confined to a mass lesion with little or no blood and marrow involvement.
        </p>
        <p>
         The clinical presentation, evaluation, and diagnosis of ALL/LBL in children are reviewed here.
        </p>
        <p>
         Risk group stratification and treatment of childhood ALL/LBL are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6248.html" rel="external">
          "Prognostic factors and risk group stratification for acute lymphoblastic leukemia/lymphoblastic lymphoma in children and adolescents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">
          "Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         ALL/LBL accounts for approximately one-third of all childhood malignancies and is the most common form of cancer in children; ALL/LBL is five times more common in children than acute myeloid leukemia (AML) [
         <a href="#rid2">
          2,3
         </a>
         ]. The distribution of ALL/LBL categories is B lineage (85 percent), T lineage (10 to 15 percent), and NK lineage (&lt;1 percent).
        </p>
        <p>
         Approximately 2500 to 3500 new cases of ALL/LBL are diagnosed in children each year in the United States, with an incidence of approximately 3.4 cases per 100,000 [
         <a href="#rid2">
          2
         </a>
         ]. The incidence varies worldwide but this may be influenced, in part, by diagnostic and reporting differences [
         <a href="#rid4">
          4
         </a>
         ]. In the United States, the incidence of ALL/LBL is higher in Latino and White individuals than in Black and Asian individuals [
         <a href="#rid5">
          5,6
         </a>
         ]. The peak incidence of ALL/LBL occurs between ages two to five years, and it is more common among boys than girls [
         <a href="#rid2">
          2,5,7,8
         </a>
         ].
        </p>
        <p>
         The incidence of childhood leukemia appears to be increasing, as demonstrated by the following studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an analysis of the Surveillance, Epidemiology, and End Results (SEER) database, there was a steady increase in ALL/LBL incidence from 2000 to 2016, with an average annual increase in incidence of approximately 1 percent [
         <a href="#rid6">
          6
         </a>
         ]. The estimated incidence increased from 25 cases per million in 1975 to 41 cases per million in 2015 [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study that used data from 63 European population-based cancer registries of children diagnosed with cancer, the incidence of leukemia, including ALL/LBL, increased by an average of 1.4 percent per year from 1970 to 1999 [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study from Great Britain, the incidence of leukemia (mostly ALL/LBL) steadily increased from 38 in the period from 1971 to 1975 to 46 per million in 1996 to 2000 [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         However, the increased incidence of ALL/LBL may also reflect more accurate reporting. A study from four Nordic countries (Denmark, Finland, Norway, and Sweden) reported that the incidence of childhood ALL/LBL remained stable at 3.3 cases per 100,000 in children &lt;15 years old from 1983 to 2002 after an increase in incidence between 1975 and 1983 [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1172758288">
         <span class="h1">
          RISK FACTORS FOR ALL/LBL
         </span>
         <span class="headingEndMark">
          —
         </span>
         The vast majority of cases of ALL/LBL have no known cause, but an increased incidence has been associated with certain environmental or genetic risk factors.
        </p>
        <p>
         Large studies have reported an increased incidence of ALL/LBL in association with advanced paternal age and maternal fetal loss (hazard ratios ≤1.1 for either) [
         <a href="#rid12">
          12-14
         </a>
         ]. A Scandinavian case control study of &gt;1900 children with ALL/LBL reported that increased birth weight was associated with increased risk for ALL/LBL (odds ratio [OR] 1.26 per 1 kg increase in birth weight; 95% CI 1.13-1.41); however, children with leukemia did not weigh more at birth than their siblings [
         <a href="#rid15">
          15
         </a>
         ]. Studies of the relationship between childhood leukemia and urban/rural status, population density, and other possible etiologic factors (eg, environmental exposures, abnormal immune response to common infections) have yielded inconsistent results [
         <a href="#rid16">
          16-29
         </a>
         ].
        </p>
        <p>
         In most cases, childhood ALL/LBL is not considered to be a familial disease. However, a Scandinavian study that included 3994 children with ALL/LBL identified 36 siblings who were subsequently diagnosed with ALL/LBL [
         <a href="#rid30">
          30
         </a>
         ]. They reported that, compared with the general population, monozygotic twin siblings of children with ALL/LBL have a much higher risk of developing leukemia (standardized incidence ratio [SIR] 163; 95% CI 70-320), while singleton siblings are at only slightly increased risk (SIR 3; 95% CI 2-6). The high risk of ALL/LBL in monozygotic twin siblings of affected children appears to stem from the spread of "pre-leukemic" clones from one twin to the second in utero [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         Certain genetic syndromes (eg, Down syndrome, neurofibromatosis type 1, Bloom syndrome, ataxia-telangiectasia) are associated with an increased risk for ALL/LBL [
         <a href="#rid32">
          32,33
         </a>
         ]. In addition, germline mutations in
         <em>
          PAX5
         </em>
         ,
         <em>
          ETV6
         </em>
         , and
         <em>
          TP53
         </em>
         predispose to the development of ALL/LBL and large-scale genomic studies have noted that polymorphic variants of
         <em>
          ARID5B
         </em>
         ,
         <em>
          CDKN2A,
         </em>
         and
         <em>
          IKZF1
         </em>
         (the gene encoding Ikaros) are associated with an increased risk of leukemia (OR: 1.3-1.9) [
         <a href="#rid34">
          34-38
         </a>
         ]. Rare examples of familial ALL/LBL syndromes are described separately. (See
         <a class="medical medical_review" href="/z/d/html/2917.html" rel="external">
          "Down syndrome: Clinical features and diagnosis", section on 'Acute lymphoblastic leukemia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/93183.html" rel="external">
          "Familial disorders of acute leukemia and myelodysplastic syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PRESENTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common presenting findings associated with ALL/LBL are nonspecific and may be difficult to distinguish from ordinary, self-limited diseases of childhood. A meta-analysis that included &gt;3000 children from 33 studies reported that more than half of children with childhood leukemia had at least one of the following five features on presentation: palpable liver, palpable spleen, pallor, fever, or bruising; 6 percent of children were asymptomatic at the time of diagnosis [
         <a href="#rid39">
          39
         </a>
         ]. Evaluation of these clinical findings is described below. (See
         <a class="local">
          'Clinical evaluation'
         </a>
         below.)
        </p>
        <p>
         Among the most common clinical findings at the time of presentation with ALL/LBL are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hepatomegaly (64 percent) and/or splenomegaly (61 percent) are the most common clinical findings in association with childhood leukemia [
         <a href="#rid39">
          39
         </a>
         ]. Organomegaly may be manifest as anorexia, weight loss, abdominal distension or abdominal pain noted by a family member or clinician.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphadenopathy is present in nearly half of children with ALL/LBL [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fever is present in more than half of children at the time of diagnosis of ALL/LBL [
         <a href="#rid39">
          39
         </a>
         ]. Fever may be caused by infection or it may represent a constitutional symptom caused by the leukemia itself.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hematologic abnormalities are common presenting findings in childhood ALL/LBL. About half of children present with bleeding (eg, petechiae, purpura) and three-quarters have a platelet count &lt;100,000/microL at diagnosis [
         <a href="#rid40">
          40
         </a>
         ]. Manifestations of anemia (eg, pallor, fatigue) are reported in more than half of children [
         <a href="#rid39">
          39
         </a>
         ]. The white blood cell (WBC) count may be low, normal, or high; WBC count is &lt;10,000/microL in one-half and &gt;50,000/microL in 20 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Musculoskeletal pain is a presenting symptom in 43 percent of cases of ALL/LBL [
         <a href="#rid39">
          39
         </a>
         ]. Young children with bone pain may present with a limp or refusal to bear weight [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Less common manifestations of ALL/LBL in children include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Headache is uncommon (&lt;5 percent of cases), but leukemia involving the central nervous system can present with headache, vomiting, lethargy, nuchal rigidity, and, rarely, with cranial nerve abnormalities [
         <a href="#rid41">
          41-43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testicular enlargement is rare (&lt;1 percent), but painless unilateral testicular enlargement can be a presenting sign of ALL/LBL. However, testicular involvement is present in up to 10 percent of boys with relapsed leukemia [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A mediastinal mass, which is most often associated with T-ALL/LBL, can cause superior vena cava (SVC) syndrome, which may manifest as pain, dysphagia, dyspnea, or swelling of the neck, face, and upper limbs due to obstruction the SVC. Respiratory distress may result from a mass compressing the trachea. (See
         <a class="medical medical_review" href="/z/d/html/15773.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3696399659">
         <span class="h1">
          CLINICAL EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H1602675443">
         <span class="h2">
          When to suspect ALL/LBL
         </span>
         <span class="headingEndMark">
          —
         </span>
         ALL/LBL should be suspected in a child with persistent unexplained pallor, fever, bleeding/bruising, bone pain, hepatosplenomegaly, and/or lymphadenopathy. In some cases, less common findings (eg, testicular swelling, neurologic findings, or evidence of tracheal obstruction or superior vena cava syndrome) may be the sole manifestation. A high degree of suspicion is required because the most common findings are nonspecific and may be difficult to distinguish from ordinary, self-limited diseases of childhood. Young children may be unable to effectively describe their symptoms. (See
         <a class="local">
          'Presentation'
         </a>
         above.)
        </p>
        <p>
         Children who are suspected of having leukemia, based on presentation and initial laboratory evaluation, should be referred promptly to a pediatric cancer specialist or pediatric cancer center for evaluation, diagnosis, and management.
        </p>
        <p class="headingAnchor" id="H1983497337">
         <span class="h2">
          History and physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical findings that may be detected by history or physical examination include (see
         <a class="local">
          'Presentation'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatosplenomegaly
         </strong>
         – Organomegaly may be detected by physical examination or the child or a family member may report anorexia, weight loss, abdominal distension or abdominal pain. Evaluation of the child with unexplained splenomegaly, including imaging and laboratory studies, is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5928.html" rel="external">
          "Approach to the child with an enlarged spleen", section on 'Evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lymphadenopathy
         </strong>
         – Persistent or progressive lymphadenopathy that does not respond to antibiotic therapy should be evaluated for ALL/LBL. Typical lymphadenopathy associated with ALL/LBL is nontender, firm, rubbery, and matted. A lymph node is generally considered enlarged when it is &gt;10 mm, except for the following nodes that are considered abnormal: epitrochlear (&gt;5 mm), inguinal (&gt;15 mm), and cervical (&gt;20 mm). Evaluation and diagnostic studies of lymphadenopathy is described separately. (See
         <a class="medical medical_review" href="/z/d/html/6243.html" rel="external">
          "Overview of common presenting signs and symptoms of childhood cancer", section on 'Lymphadenopathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fever
         </strong>
         – Recurrent fevers, failure to respond to seemingly appropriate treatment, drenching sweats, or unexplained weight loss should prompt evaluation for underlying leukemia. Fever may be caused by infection or it may be a constitutional symptom caused by the leukemia itself. Assessment of a child with unexplained fever or other constitutional symptoms that may be attributable to leukemia is described separately. (See
         <a class="medical medical_review" href="/z/d/html/6243.html" rel="external">
          "Overview of common presenting signs and symptoms of childhood cancer", section on 'Constitutional symptoms'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologic findings
         </strong>
         – Pallor, persistent fatigue, unusual bleeding/bruising, or petechial rash are common manifestations of ALL/LBL in children. Evaluation of children with anemia or thrombocytopenia is described separately. (See
         <a class="medical medical_review" href="/z/d/html/5927.html" rel="external">
          "Approach to the child with anemia", section on 'Evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5939.html" rel="external">
          "Approach to the child with unexplained thrombocytopenia", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Musculoskeletal pain
         </strong>
         – Bone pain is common as a presenting symptom, but young children may instead present with a limp or refusal to bear weight. Joint pain caused by ALL/LBL may be mistaken for rheumatologic pain. Diagnostic evaluation in children and features that may distinguish leukemia-associated musculoskeletal pain from other causes are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6243.html" rel="external">
          "Overview of common presenting signs and symptoms of childhood cancer", section on 'Bone and joint pain'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurologic findings
         </strong>
         – Leukemia involving the central nervous system can present with symptoms related to increased intracranial pressure, including headache, vomiting, lethargy, and/or nuchal rigidity [
         <a href="#rid41">
          41
         </a>
         ]. Rarely, leukemia can present with cranial nerve abnormalities [
         <a href="#rid42">
          42,43
         </a>
         ]. Neurologic findings from the history and physical examination should be evaluated promptly by imaging and/or lumbar puncture (LP). As described below,
         <strong>
          all
         </strong>
         children who are diagnosed with ALL/LBL must have a diagnostic/therapeutic LP at the time that treatment is initiated, regardless of whether neurologic abnormalities are found. (See
         <a class="local">
          'Lumbar puncture/neurologic evaluation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Testicular enlargement
         </strong>
         – A persistent, painless, solid testicular mass should be referred for biopsy by a pediatric surgeon after evaluation by ultrasound. (See
         <a class="medical medical_review" href="/z/d/html/6448.html" rel="external">
          "Causes of painless scrotal swelling in children and adolescents", section on 'Testicular cancer'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Respiratory distress
         </strong>
         – Tachypnea, inspiratory stridor, wheezing, suprasternal/supraclavicular retractions, prolonged inspiratory phase, drooling, or other findings that may suggest upper airway obstruction should be evaluated and managed, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6455.html" rel="external">
          "Emergency evaluation of acute upper airway obstruction in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Swelling of face, neck, or upper extremities
         </strong>
         – A large anterior mediastinal mass (typically associated with T-lineage ALL/LBL) may be manifest as swelling of the neck, face, and upper limbs, or with pain, dysphagia, or dyspnea. (See
         <a class="medical medical_review" href="/z/d/html/2832.html" rel="external">
          "Malignancy-related superior vena cava syndrome", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3344723619">
         <span class="h1">
          LABORATORY EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H1530528834">
         <span class="h2">
          Laboratory studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory evaluation for ALL/LBL includes a complete blood count (CBC) and differential count, review of the peripheral smear, and bone marrow examination. When lymphadenopathy is a prominent component of the clinical presentation, the evaluation may begin with evaluation of a suspicious lymph node. If so, an excisional or needle core biopsy is preferable to a fine needle aspirate in order to evaluate abnormal node architecture and to provide sufficient material for a thorough pathologic examination. (See
         <a class="medical medical_review" href="/z/d/html/2867.html" rel="external">
          "Peripheral lymphadenopathy in children: Evaluation and diagnostic approach", section on 'Lymph node biopsy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3904615230">
         <span class="h2">
          Morphology
         </span>
         <span class="headingEndMark">
          —
         </span>
         Morphology of cells from peripheral blood, bone marrow, or other tissues may be variable, but characteristic morphology  (
         <a class="graphic graphic_picture graphicRef83240" href="/z/d/graphic/83240.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef83239" href="/z/d/graphic/83239.html" rel="external">
          picture 2
         </a>
         ) is an essential component of the diagnosis of ALL/LBL, as described below. (See
         <a class="local">
          'Diagnosis of ALL/LBL'
         </a>
         below.)
        </p>
        <p>
         Lymphoblasts of ALL/LBL can be morphologically indistinguishable from a variety of other disorders. Features that distinguish ALL/LBL from other malignant and nonmalignant conditions are discussed below. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3617232838">
         <span class="h2">
          Cytochemistry
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cytochemical studies have some value in evaluating suspected cases of leukemia, but are not required to establish the diagnosis of ALL/LBL. Examples of cytochemical findings associated with ALL/LBL include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Periodic acid-Schiff (PAS)
         </strong>
         – Lymphoblasts may reveal coarse ("chunky") PAS-positive granules, a finding present in only a subset of cases; this staining pattern is due to the presence of glycogen, which may also be present in some blasts of myeloid origin (particularly erythroblasts)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonspecific esterase (NSE)
         </strong>
         – Staining is usually absent, but weak multifocal punctate or Golgi region staining may be seen
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myeloperoxidase (MPO)
         </strong>
         – By definition, MPO is negative in ALL/LBL, since peroxidase is considered a lineage-defining myeloid marker
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4067510921">
         <span class="h2">
          Flow cytometry/immunohistochemistry
         </span>
         <span class="headingEndMark">
          —
         </span>
         Flow cytometry and/or immunohistochemistry may be used to characterize the immunophenotype of lymphoblasts from peripheral blood, bone marrow, a lymph node, or other tissue (eg, pleural fluid).
        </p>
        <p>
         Immunophenotypic characterization should include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lymphoid antigens:
         </strong>
         B cell (eg, CD19, CD20, CD22, CD79a, PAX5), T cell (eg, CD1a, CD3, CD4, CD5, CD7, CD8), NK cell (eg, CD56), and markers of immature lymphoid cells (CD10, terminal deoxyribonucleotide transferase [TdT]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Markers of intermediate (CD10) and late (CD20) stages of pre-B cell maturation are variably expressed, depending on the stage of maturation arrest of the B lymphoblasts. (See
         <a class="medical medical_review" href="/z/d/html/4686.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma", section on 'Evaluation and diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         T lymphoblasts are usually also positive for CD2, CD5, and CD7, and variable combinations of CD1a, CD4, CD8, and CD10 may be expressed, depending on the stage of maturation arrest. (See
         <a class="medical medical_review" href="/z/d/html/15773.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma", section on 'Evaluation and diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Myeloid antigens:
         </strong>
         (eg, CD13, CD33, CD11b, CD64)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maturation antigens:
         </strong>
         (eg, CD34, CD117, HLA-DR)
        </p>
        <p>
        </p>
        <p>
         Aspects of the immunophenotype that are required for diagnosis and classification of ALL/LBL are described below. (See
         <a class="local">
          'Diagnosis of ALL/LBL'
         </a>
         below and
         <a class="local">
          'WHO classification'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H563763463">
         <span class="h2">
          Cytogenetic/molecular features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cytogenetic and molecular features are not required for diagnosis, but they are essential criteria for World Health Organization classification of ALL/LBL [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'WHO classification'
         </a>
         below.)
        </p>
        <p>
         Chromosome banding techniques and fluorescence in situ hybridization (FISH) are used to characterize cytogenetic features, while a variety of molecular techniques are used for mutation analysis and gene expression studies [
         <a href="#rid45">
          45,46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4482.html" rel="external">
          "General aspects of cytogenetic analysis in hematologic malignancies", section on 'Examination of tumor specimens'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14602.html" rel="external">
          "Tools for genetics and genomics: Gene expression profiling"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17039.html" rel="external">
          "Next-generation DNA sequencing (NGS): Principles and clinical applications"
         </a>
         .)
        </p>
        <p>
         Rearrangement of immunoglobulin and T cell receptor genes in ALL/LBL is variable, not lineage-specific, and is not a reliable method for distinguishing between B and T cell lineages. (See
         <a class="medical medical_review" href="/z/d/html/4686.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma", section on 'Cytogenetic/Molecular analysis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1730647161">
         <span class="h1">
          DIAGNOSIS OF ALL/LBL
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of ALL/LBL requires characteristic morphology and a diagnostic immunophenotype of cells from peripheral blood, bone marrow, lymph node, and/or other involved tissue:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Morphology may vary from small cells with scant cytoplasm, condensed nuclear chromatin, and indistinct nucleoli  (
         <a class="graphic graphic_picture graphicRef83240" href="/z/d/graphic/83240.html" rel="external">
          picture 1
         </a>
         ) to larger cells with moderate amounts of cytoplasm, dispersed chromatin, and multiple nucleoli; coarse azurophilic cytoplasmic granules may be present, but Auer rods are absent [
         <a href="#rid1">
          1
         </a>
         ]. The appearance of lymphoblasts in biopsy specimens is relatively uniform  (
         <a class="graphic graphic_picture graphicRef83239" href="/z/d/graphic/83239.html" rel="external">
          picture 2
         </a>
         ), but the cells may include round, oval, indented, or convoluted nuclei, finely dispersed chromatin, and nucleoli that can range from inconspicuous to prominent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Features that distinguish ALL/LBL from other disorders are described below. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diagnostic immunophenotype of ALL/LBL requires confirmation of lymphoid lineage and exclusion of myeloid lineage by flow cytometry and/or cytochemistry [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Lymphoblast lineage is defined as one of the following (see
         <a class="local">
          'Flow cytometry/immunohistochemistry'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         B-lineage lymphoblasts are almost always positive for the B cell markers CD19, cytoplasmic CD79a, and cytoplasmic CD22; although none of the B cell markers by itself is specific for B-lineage ALL/LBL, their positivity in combination or high intensity expression strongly supports the diagnosis.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         B lymphoblasts must be negative for CD3 (T cell antigen) and negative for myeloperoxidase (MPO); however, in some cases, expression of certain myeloid antigens (eg, CD13, CD33) does not exclude a diagnosis of ALL/LBL, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/4686.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma", section on 'Evaluation and diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         T-lineage lymphoblasts are positive for cytoplasmic or surface CD3, and negative for B cell antigens and MPO.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Other: Criteria for diagnosis of NK-ALL/LBL and early T cell precursor ALL/LBL are controversial and/or evolving [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Although there is no consensus regarding a minimal proportion of lymphoblasts in bone marrow, the diagnosis of B-ALL/LBL should be avoided when there are &lt;20 percent lymphoblasts [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1842345211">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presenting signs and symptoms of ALL/LBL are often nonspecific and morphology alone is not diagnostic, so it is important to consider a wide range of malignant and nonmalignant conditions in the differential diagnosis.
        </p>
        <p class="headingAnchor" id="H2014645703">
         <span class="h2">
          Malignant disorders
         </span>
        </p>
        <p class="headingAnchor" id="H3806335661">
         <span class="h3">
          Burkitt lymphoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Burkitt lymphoma (BL) is a highly aggressive B cell non-Hodgkin lymphoma that can present with a rapidly growing tumor mass (eg, jaw or abdominal mass) and/or as a leukemia. BL can have substantial clinical and morphologic overlap with ALL/LBL. The histology of BL typically reveals highly proliferative monomorphic medium-sized cells with basophilic cytoplasm (often with a "starry sky" appearance)  (
         <a class="graphic graphic_picture graphicRef59619" href="/z/d/graphic/59619.html" rel="external">
          picture 3
         </a>
         ) that are generally larger than ALL/LBL lymphoblasts. The diagnosis of BL is based on morphology, immunophenotype, and cytogenetic/molecular features and is distinguished from ALL/LBL by the characteristic mature germinal center B cell immunophenotype and translocation involving chromosome 8 and/or
         <em>
          MYC
         </em>
         rearrangement, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4700.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3066588733">
         <span class="h3">
          Other acute leukemias
         </span>
         <span class="headingEndMark">
          —
         </span>
         ALL/LBL lymphoblasts may be difficult to distinguish morphologically from other forms of acute leukemia, particularly those that are minimally differentiated:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute myeloid leukemia (AML)
         </strong>
         – Myeloblasts of AML are typically immature cells with large nuclei, prominent nucleoli, and a variable amount of pale blue cytoplasm (sometimes with faint granulation and/or Auer rods). AML cells generally stain for myeloperoxidase (MPO) or lysozyme and are typically negative for B and T cell antigens and TdT; some cases of AML express antigens associated with stem cells or lymphoid lineages. Other aspects of the diagnosis of AML are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acute undifferentiated leukemia (AUL)
         </strong>
         – AUL blast cells are morphologically bland and generally indistinguishable from those of B-ALL/LBL. These entities are distinguished by immunophenotype; AUL blasts do not express lineage-specific antigens by flow cytometry or immunohistochemistry, whereas ALL/LBL blasts express B- or T-lymphoid antigens. (See
         <a class="medical medical_review" href="/z/d/html/116801.html" rel="external">
          "Mixed phenotype acute leukemia", section on 'Acute undifferentiated leukemia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mixed phenotype acute leukemia (MPAL)
         </strong>
         – Diagnosis of MPAL requires demonstration of both myeloid- and lymphoid-defining markers by flow cytometry and/or immunohistochemistry. (See
         <a class="medical medical_review" href="/z/d/html/116801.html" rel="external">
          "Mixed phenotype acute leukemia", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2240583659">
         <span class="h3">
          Chronic myeloid leukemia (CML)
         </span>
         <span class="headingEndMark">
          —
         </span>
         CML is typically manifested as an expanded population of myeloid cells at various stages of differentiation with the characteristic t(9;22) (Philadelphia chromosome) with
         <em>
          BCR
         </em>
         -
         <em>
          ABL1
         </em>
         rearrangement that may be accompanied by splenomegaly and/or constitutional symptoms. However, about 10 percent of CML in blast phase may have a dominant population of lymphoblasts. CML can be distinguished from ALL/LBL by detection of t(9;22) or
         <em>
          BCR-ABL1
         </em>
         in myeloid cells. (See
         <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">
          "Clinical manifestations and diagnosis of chronic myeloid leukemia", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H244849312">
         <span class="h3">
          Myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2
         </span>
         <span class="headingEndMark">
          —
         </span>
         These rare neoplasms often present with lymphadenopathy due to proliferation of T-lineage (or less commonly, B-lineage) lymphoblasts that are morphologically and immunophenotypically indistinguishable from conventional LBL [
         <a href="#rid1">
          1
         </a>
         ]. The characteristic gene rearrangements are also present in myeloid cells as well as the lymphoblasts, and these disorders should be suspected if examination of the blood reveals leukocytosis and eosinophilia. They are diagnosed based on identification of one of the pathogenic gene rearrangements (listed above), typically by fluorescence in situ hybridization (FISH). (See
         <a class="medical medical_review" href="/z/d/html/2211.html" rel="external">
          "Hypereosinophilic syndromes: Clinical manifestations, pathophysiology, and diagnosis", section on 'HES variants'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2139834270">
         <span class="h3">
          Aplastic anemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aplastic anemia (AA) may present in children as pancytopenia with reticulocytopenia (frequently &lt;10,000/microL) and profoundly hypocellular bone marrow with a decrease in all hematopoietic elements. In contrast to ALL/LBL, there is no infiltrate of malignant cells in AA; instead, the marrow space is largely composed of fat cells and marrow stroma.
        </p>
        <p class="headingAnchor" id="H3553861599">
         <span class="h3">
          Small round blue cell tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         In children, small round blue cell tumors, including Ewing sarcoma (ES) and peripheral primitive neuroectodermal tumor (PNET) may resemble B-ALL/LBL morphologically, but these disorders are distinguished by a uniform population of small, round, blue cells with hyperchromatic nuclei and scant cytoplasm; absence of B-lymphoid markers; and may include certain cytogenetic/molecular findings (eg, t(11;22)(q24;q12),
         <em>
          EWSR1
         </em>
         -
         <em>
          FLI1
         </em>
         rearrangement). Diagnosis and differential diagnosis of such tumors are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7742.html" rel="external">
          "Epidemiology, pathology, and molecular genetics of Ewing sarcoma", section on 'Histologic features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2461835069">
         <span class="h2">
          Nonmalignant disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presenting signs and symptoms of ALL/LBL are nonspecific, and certain nonmalignant disorders may resemble ALL/LBL clinically and/or exhibit lymphocytes that may resemble lymphoblasts.
        </p>
        <p>
         The following disorders may be included in the differential diagnosis in children:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immune thrombocytopenia (ITP) is associated with isolated thrombocytopenia that can resemble ALL/LBL clinically. The diagnosis of ITP in a healthy-appearing child with a typical presentation (ie, sudden onset of a petechial rash or bruising with isolated thrombocytopenia) is straightforward. Thrombocytopenia in ITP, especially in the context of an otherwise normal complete blood count, is typically more severe than in ALL/LBL. In contrast, thrombocytopenia in ALL/LBL is almost always associated with other clinical and laboratory findings (eg, fever, bone pain, weight loss, hepatosplenomegaly, lymphadenopathy, leukocytosis, anemia, peripheral blood lymphoblasts). When the diagnosis is uncertain, bone marrow examination and/or flow cytometry will distinguish ALL/LBL from ITP. (See
         <a class="medical medical_review" href="/z/d/html/5930.html" rel="external">
          "Immune thrombocytopenia (ITP) in children: Clinical features and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infectious disease and other causes of lymphocytosis and/or aberrant lymphocytes include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Human immunodeficiency virus (HIV)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infectious mononucleosis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pertussis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Osteomyelitis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tuberculosis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Heavy metal toxicity
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Thymoma
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Autoimmune diseases (including juvenile rheumatoid arthritis in children)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Distinguishing these disorders from ALL/LBL in children is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8387.html" rel="external">
          "Approach to the child with lymphocytosis or lymphocytopenia", section on 'Causes of reactive lymphocytosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3702717413">
         <span class="h1">
          WHO CLASSIFICATION
         </span>
        </p>
        <p class="headingAnchor" id="H2256704797">
         <span class="h2">
          Studies used for classification
         </span>
         <span class="headingEndMark">
          —
         </span>
         World Health Organization (WHO) classification of ALL/LBL requires characterization of cytogenetic and molecular features [
         <a href="#rid1">
          1
         </a>
         ]. Cytogenetic features are characterized by chromosome banding techniques and fluorescence in situ hybridization (FISH), while a variety of molecular techniques are used for mutation analysis and gene expression studies [
         <a href="#rid45">
          45,46
         </a>
         ]. Certain categories of ALL/LBL require additional specialized molecular techniques (eg, gene expression techniques or other analyses that are used to classify
         <em>
          BCR::ABL1-
         </em>
         like ALL, as described separately). (See
         <a class="medical medical_review" href="/z/d/html/4484.html" rel="external">
          "Classification, cytogenetics, and molecular genetics of acute lymphoblastic leukemia/lymphoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2893.html" rel="external">
          "Tools for genetics and genomics: Cytogenetics and molecular genetics"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2898462587">
         <span class="h2">
          B-ALL/LBL
         </span>
         <span class="headingEndMark">
          —
         </span>
         All cases of B-ALL/LBL should be categorized according to the WHO classification  (
         <a class="graphic graphic_table graphicRef110239" href="/z/d/graphic/110239.html" rel="external">
          table 1
         </a>
         ), because of their prognostic significance and/or distinctive requirements for therapy [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         B-ALL/LBL, not otherwise specified (NOS)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         B-ALL/LBL with recurrent genetic abnormalities:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Philadelphia chromosome (Ph+); t(9;22)(q34.1; q11.2);
         <em>
          BCR::ABL1
         </em>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         t(v;11q23.3);
         <em>
          KMT2A
         </em>
         -rearranged
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         t(12;21)(p13.2;q22.1);
         <em>
          ETV6::RUNX1
         </em>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hyperdiploid B-ALL/LBL
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypodiploid B-ALL/LBL
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         t(5;14)(q31.1;q32.1);
         <em>
          IGH::IL3
         </em>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         t(1;19)(q23;p13.3);
         <em>
          TCF3::PBX1
         </em>
        </p>
        <p>
        </p>
        <p>
         In addition, two provisional entities with distinct genetic signatures that are associated with adverse prognosis are recognized in the WHO classification [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         BCR::ABL1-like (Ph-like)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         iAMP21
        </p>
        <p>
        </p>
        <p>
         Details of criteria for WHO classification of B-ALL/LBL are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/4686.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of B cell acute lymphoblastic leukemia/lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1000622553">
         <span class="h2">
          T-ALL/LBL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunophenotype is used to classify T-ALL/LBL and related entities [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          T-ALL/LBL:
         </strong>
         Defined by the presence of cytoplasmic or surface CD3, and can be further subdivided into cortical and medullary subtypes based on combinations of T lineage markers; lineage-defining B and myeloid cell markers are negative.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early T cell precursor lymphoblastic leukemia:
         </strong>
         A provisional diagnostic entity in the 2016 WHO classification that is always
         <strong>
         </strong>
         CD7 positive and usually positive for CD2 and cytoplasmic CD3; variably positive for CD4 and CD5; CD1a and CD8 negative; and positive for at least one of the following: CD34, CD117 (
         <em>
          KIT
         </em>
         ), HLA-DR, CD13, CD33, CD11b, or CD65.
        </p>
        <p>
        </p>
        <p>
         Additional features that distinguish categories of T-ALL/LBL are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/15773.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma", section on 'Pathologic features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3435927111">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In addition to the studies that are required to establish the diagnosis of ALL/LBL, the following tests should be performed in advance of treatment.
        </p>
        <p class="headingAnchor" id="H3910704662">
         <span class="h2">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory studies to evaluate potential complications of ALL/LBL (eg, coagulation abnormalities, liver or kidney dysfunction, metabolic abnormalities, tumor lysis syndrome) include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Coagulation profile:
         </strong>
         Prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemistries:
         </strong>
         Electrolytes, renal and liver function tests, calcium, phosphate, lactate dehydrogenase (LDH), uric acid
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2291939365">
         <span class="h2">
          Lumbar puncture/neurologic evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         All children who are diagnosed with ALL/LBL must undergo a lumbar puncture (LP) prior to beginning therapy to evaluate potential leukemic involvement of the central nervous system (CNS)
         <strong>
          and
         </strong>
         concomitantly administer the first dose of intrathecal therapy, as described separately. (See
         <a class="medical medical_review" href="/z/d/html/6245.html" rel="external">
          "Treatment of acute lymphoblastic leukemia/lymphoma in children and adolescents", section on 'CNS management'
         </a>
         .)
        </p>
        <p>
         Results from the LP are categorized as one of the following, which are used for determining the schedule of CNS prophylaxis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CNS-1:
         </strong>
         No lymphoblasts in cerebrospinal fluid (CSF) regardless of the white blood cell count
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CNS-2:
         </strong>
         &lt;5 white blood cells (WBC)/microL in CSF with the presence of lymphoblasts
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CNS-3:
         </strong>
         ≥5 WBC/microL in CSF with the presence of lymphoblasts
        </p>
        <p>
        </p>
        <p>
         Neurologic findings from the history and physical exam should be evaluated promptly by imaging (eg, magnetic resonance imaging [MRI] or computed tomography [CT]) and/or urgent LP. Selection of the imaging modality is described separately. (See
         <a class="medical medical_review" href="/z/d/html/6250.html" rel="external">
          "Clinical manifestations and diagnosis of central nervous system tumors in children", section on 'Neuroimaging'
         </a>
         .)
        </p>
        <p>
         Performance of a diagnostic LP in a child and the evaluation of CSF are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6325.html" rel="external">
          "Lumbar puncture in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1285.html" rel="external">
          "Cerebrospinal fluid: Physiology and utility of an examination in disease states", section on 'Composition of the CSF'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2465918386">
         <span class="h2">
          Other pretreatment tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other studies that should be performed before the initiation of treatment for ALL/LBL include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection evaluation:
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Screen for active infections if the child is febrile, and initiate empiric treatment, as appropriate (see
         <a class="medical medical_review" href="/z/d/html/6059.html" rel="external">
          "Management of children with non-chemotherapy-induced neutropenia and fever"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Some experts also include baseline viral titers in all children, including cytomegalovirus, Epstein-Barr virus, HIV, and hepatitis B virus
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiac evaluation
         </strong>
         – Echocardiogram or cardiac scan should be performed to assess cardiac function in anticipation of treatment that includes an anthracycline.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Human leukocyte antigen (HLA) typing
         </strong>
         – Some experts perform HLA typing in the event that hematopoietic cell transplantation will be required for later management.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CT of chest
         </strong>
         – For patients who are diagnosed with T-ALL/LBL, a CT scan of the chest, with contrast if possible, should be performed to evaluate the presence of a mediastinal mass. (See
         <a class="medical medical_review" href="/z/d/html/15773.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma", section on 'Clinical presentation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2405020836">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119662.html" rel="external">
          "Society guideline links: Acute lymphoblastic leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9940340">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83252.html" rel="external">
          "Patient education: Leukemia in children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         – Acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL) refers to malignancies of precursor lymphoid cells; it is called ALL/LBL because leukemia and lymphoma are overlapping clinical presentations of the same disease  (
         <a class="graphic graphic_table graphicRef110239" href="/z/d/graphic/110239.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – ALL/LBL is the most common cancer in children, with peak incidence at two to five years of age. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes
         </strong>
         – Most cases have no identifiable environmental or genetic cause. Incidence is increased in Down syndrome and other constitutional genetic disorders. (See
         <a class="local">
          'Risk factors for ALL/LBL'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Presentation
         </strong>
         – Most children present with nonspecific symptoms that are difficult to distinguish from ordinary, self-limited diseases of childhood. Most often, children present with persistent pallor, fever, bleeding/bruising, bone pain, hepatosplenomegaly, or lymphadenopathy. Less common findings include testicular swelling, tracheal obstruction, superior vena cava syndrome, or neurologic findings. (See
         <a class="local">
          'Presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial evaluation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clinical
         </strong>
         – History and physical examination should evaluate the clinical findings listed above.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Laboratory
         </strong>
         – Initial studies include complete blood count (CBC)/differential count and review of blood smear for circulating lymphoblasts  (
         <a class="graphic graphic_picture graphicRef83240" href="/z/d/graphic/83240.html" rel="external">
          picture 1
         </a>
         ). (See
         <a class="local">
          'Laboratory studies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic evaluation
         </strong>
         – ALL/LBL should be suspected in children with the clinical findings described above or unexplained lymphocytosis, cytopenias, or circulating blasts. Such children should be referred promptly to a pediatric cancer specialist or pediatric cancer center for evaluation, diagnosis, and management.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bone marrow (BM) examination
         </strong>
         – A BM specimen is generally required to establish the diagnosis of ALL/LBL. The specimen is analyzed by microscopy, immunophenotyping (usually by flow cytometry), cytogenetics, and molecular studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other tissues
         </strong>
         – If the clinical situation precludes BM examination, the diagnosis can be based on:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Blood
         </strong>
         – Diagnosis requires adequate circulating lymphoblasts (eg, ≥1000 cells/microL).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Lymph node
         </strong>
         – If LBL is the predominant/exclusive presentation, the diagnosis can be established from a lymph node or other lymphoid tissue. BM should also be examined, if possible, to rule out involvement of both sites.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Diagnosis of ALL/LBL requires ≥20 percent lymphoblasts in BM  (
         <a class="graphic graphic_picture graphicRef83239" href="/z/d/graphic/83239.html" rel="external">
          picture 2
         </a>
         ), with an immunophenotype that confirms the lymphoid lineage and excludes a myeloid lineage. Occasionally the diagnosis can be established with a compatible finding in blood or a lymph node. Malignant blasts may indicate B cell lineage (85 percent), T cell lineage (10 to 15 percent), or NK cell lineage (&lt;1 percent)  (
         <a class="graphic graphic_table graphicRef110239" href="/z/d/graphic/110239.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Diagnosis of ALL/LBL'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The differential diagnosis of ALL/LBL is broad because the clinical presentation is often nonspecific and lymphoblast morphology is not diagnostic. The differential diagnosis of children with unexplained cytopenias, lymphadenopathy, or circulating aberrant lymphoid cells/blasts includes viral infections, aplastic anemia, other cancers, and other hematologic malignancies, including Burkitt lymphoma and acute myeloid leukemia. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014; 64:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhojwani D, Yang JJ, Pui CH. Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am 2015; 62:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steliarova-Foucher E, Colombet M, Ries LAG, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol 2017; 18:719.
          </a>
         </li>
         <li class="breakAll">
          Ries LG, Smith MA, Gurney JG, et al. (eds). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program. NIH Pub. No. 99-4649. Bethesda, MD, 1999.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feng Q, de Smith AJ, Vergara-Lluri M, et al. Trends in Acute Lymphoblastic Leukemia Incidence in the United States by Race/Ethnicity From 2000 to 2016. Am J Epidemiol 2021; 190:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Svendsen AL, Feychting M, Klaeboe L, et al. Time trends in the incidence of acute lymphoblastic leukemia among children 1976-2002: a population-based Nordic study. J Pediatr 2007; 151:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012; 119:34.
          </a>
         </li>
         <li class="breakAll">
          SEER Cancer Statistics Review, 1975-2013, Howlader N, Noone AM, Krapcho M, et al (Eds), National Cancer Institute, Bethesda, MD 2015.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steliarova-Foucher E, Stiller C, Kaatsch P, et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study. Lancet 2004; 364:2097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah A, Coleman MP. Increasing incidence of childhood leukaemia: a controversy re-examined. Br J Cancer 2007; 97:1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petridou ET, Georgakis MK, Erdmann F, et al. Advanced parental age as risk factor for childhood acute lymphoblastic leukemia: results from studies of the Childhood Leukemia International Consortium. Eur J Epidemiol 2018; 33:965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Contreras ZA, Hansen J, Ritz B, et al. Parental age and childhood cancer risk: A Danish population-based registry study. Cancer Epidemiol 2017; 49:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karalexi MA, Dessypris N, Skalkidou A, et al. Maternal fetal loss history and increased acute leukemia subtype risk in subsequent offspring: a systematic review and meta-analysis. Cancer Causes Control 2017; 28:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hjalgrim LL, Rostgaard K, Hjalgrim H, et al. Birth weight and risk for childhood leukemia in Denmark, Sweden, Norway, and Iceland. J Natl Cancer Inst 2004; 96:1549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adelman AS, McLaughlin CC, Wu XC, et al. Urbanisation and incidence of acute lymphocytic leukaemia among United States children aged 0-4. Br J Cancer 2005; 92:2084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greaves M. Infection, immune responses and the aetiology of childhood leukaemia. Nat Rev Cancer 2006; 6:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kroll ME, Draper GJ, Stiller CA, Murphy MF. Childhood leukemia incidence in Britain, 1974-2000: time trends and possible relation to influenza epidemics. J Natl Cancer Inst 2006; 98:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kroll ME, Swanson J, Vincent TJ, Draper GJ. Childhood cancer and magnetic fields from high-voltage power lines in England and Wales: a case-control study. Br J Cancer 2010; 103:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kheifets L, Ahlbom A, Crespi CM, et al. Pooled analysis of recent studies on magnetic fields and childhood leukaemia. Br J Cancer 2010; 103:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urayama KY, Ma X, Selvin S, et al. Early life exposure to infections and risk of childhood acute lymphoblastic leukemia. Int J Cancer 2011; 128:1632.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reid A, Glass DC, Bailey HD, et al. Risk of childhood acute lymphoblastic leukaemia following parental occupational exposure to extremely low frequency electromagnetic fields. Br J Cancer 2011; 105:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kroll ME, Stiller CA, Murphy MF, Carpenter LM. Childhood leukaemia and socioeconomic status in England and Wales 1976-2005: evidence of higher incidence in relatively affluent communities persists over time. Br J Cancer 2011; 105:1783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang JS, Tsai YW, Tsai CR, Wiemels JL. Allergy and risk of childhood acute lymphoblastic leukemia: a population-based and record-based study. Am J Epidemiol 2012; 176:970.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bithell JF, Murphy MF, Stiller CA, et al. Leukaemia in young children in the vicinity of British nuclear power plants: a case-control study. Br J Cancer 2013; 109:2880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krestinina LY, Davis FG, Schonfeld S, et al. Leukaemia incidence in the Techa River Cohort: 1953-2007. Br J Cancer 2013; 109:2886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bunch KJ, Keegan TJ, Swanson J, et al. Residential distance at birth from overhead high-voltage powerlines: childhood cancer risk in Britain 1962-2008. Br J Cancer 2014; 110:1402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boothe VL, Boehmer TK, Wendel AM, Yip FY. Residential traffic exposure and childhood leukemia: a systematic review and meta-analysis. Am J Prev Med 2014; 46:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pedersen C, Johansen C, Schüz J, et al. Residential exposure to extremely low-frequency magnetic fields and risk of childhood leukaemia, CNS tumour and lymphoma in Denmark. Br J Cancer 2015; 113:1370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kharazmi E, da Silva Filho MI, Pukkala E, et al. Familial risks for childhood acute lymphocytic leukaemia in Sweden and Finland: far exceeding the effects of known germline variants. Br J Haematol 2012; 159:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greaves M. A causal mechanism for childhood acute lymphoblastic leukaemia. Nat Rev Cancer 2018; 18:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med 2015; 373:1541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buffler PA, Kwan ML, Reynolds P, Urayama KY. Environmental and genetic risk factors for childhood leukemia: appraising the evidence. Cancer Invest 2005; 23:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treviño LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet 2009; 41:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. Nat Genet 2009; 41:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherborne AL, Hosking FJ, Prasad RB, et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet 2010; 42:492.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu H, Yang W, Perez-Andreu V, et al. Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. J Natl Cancer Inst 2013; 105:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudant J, Orsi L, Bonaventure A, et al. ARID5B, IKZF1 and non-genetic factors in the etiology of childhood acute lymphoblastic leukemia: the ESCALE study. PLoS One 2015; 10:e0121348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarke RT, Van den Bruel A, Bankhead C, et al. Clinical presentation of childhood leukaemia: a systematic review and meta-analysis. Arch Dis Child 2016; 101:894.
          </a>
         </li>
         <li class="breakAll">
          Rabin KR, Gramatges MM, Margolin JF, et al. Acute Lymphoblastic Leukemia. In: Principles and Practice of Pediatric Oncology, 7th edition, Pizzo PA, Poplack DG (Eds), Wolters Kluwer, Philadelphia 2015.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bleyer WA. Central nervous system leukemia. Pediatr Clin North Am 1988; 35:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ingram LC, Fairclough DL, Furman WL, et al. Cranial nerve palsy in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Cancer 1991; 67:2262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paryani SB, Donaldson SS, Amylon MD, Link MP. Cranial nerve involvement in children with leukemia and lymphoma. J Clin Oncol 1983; 1:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nachman J, Palmer NF, Sather HN, et al. Open-wedge testicular biopsy in childhood acute lymphoblastic leukemia after two years of maintenance therapy: diagnostic accuracy and influence on outcome--a report from Children's Cancer Study Group. Blood 1990; 75:1051.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison CJ. The detection and significance of chromosomal abnormalities in childhood acute lymphoblastic leukaemia. Blood Rev 2001; 15:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison CJ, Moorman AV, Barber KE, et al. Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study. Br J Haematol 2005; 129:520.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6244 Version 46.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24488779" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Childhood and adolescent cancer statistics, 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25435111" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Biology of childhood acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28410997" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : International incidence of childhood cancer, 2001-10: a population-based registry study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28410997" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : International incidence of childhood cancer, 2001-10: a population-based registry study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33034340" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Trends in Acute Lymphoblastic Leukemia Incidence in the United States by Race/Ethnicity From 2000 to 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17961705" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Time trends in the incidence of acute lymphoblastic leukemia among children 1976-2002: a population-based Nordic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22086414" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22086414" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15589307" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17712312" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Increasing incidence of childhood leukaemia: a controversy re-examined.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29761423" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Advanced parental age as risk factor for childhood acute lymphoblastic leukemia: results from studies of the Childhood Leukemia International Consortium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28715709" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Parental age and childhood cancer risk: A Danish population-based registry study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28401353" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Maternal fetal loss history and increased acute leukemia subtype risk in subsequent offspring: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15494605" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Birth weight and risk for childhood leukemia in Denmark, Sweden, Norway, and Iceland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15886703" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Urbanisation and incidence of acute lymphocytic leukaemia among United States children aged 0-4.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16467884" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Infection, immune responses and the aetiology of childhood leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16537835" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Childhood leukemia incidence in Britain, 1974-2000: time trends and possible relation to influenza epidemics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20877338" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Childhood cancer and magnetic fields from high-voltage power lines in England and Wales: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20877339" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Pooled analysis of recent studies on magnetic fields and childhood leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21280034" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Early life exposure to infections and risk of childhood acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21915123" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Risk of childhood acute lymphoblastic leukaemia following parental occupational exposure to extremely low frequency electromagnetic fields.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22027710" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Childhood leukaemia and socioeconomic status in England and Wales 1976-2005: evidence of higher incidence in relatively affluent communities persists over time.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23171876" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Allergy and risk of childhood acute lymphoblastic leukemia: a population-based and record-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24030074" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Leukaemia in young children in the vicinity of British nuclear power plants: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24129230" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Leukaemia incidence in the Techa River Cohort: 1953-2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24504371" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Residential distance at birth from overhead high-voltage powerlines: childhood cancer risk in Britain 1962-2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24650845" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Residential traffic exposure and childhood leukemia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26484412" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Residential exposure to extremely low-frequency magnetic fields and risk of childhood leukaemia, CNS tumour and lymphoma in Denmark.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23025517" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Familial risks for childhood acute lymphocytic leukaemia in Sweden and Finland: far exceeding the effects of known germline variants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29784935" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A causal mechanism for childhood acute lymphoblastic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26465987" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Acute Lymphoblastic Leukemia in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15779869" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Environmental and genetic risk factors for childhood leukemia: appraising the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19684603" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Germline genomic variants associated with childhood acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19684604" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20453839" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23512250" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25806972" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : ARID5B, IKZF1 and non-genetic factors in the etiology of childhood acute lymphoblastic leukemia: the ESCALE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27647842" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical presentation of childhood leukaemia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27647842" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical presentation of childhood leukaemia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3047654" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Central nervous system leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2013032" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cranial nerve palsy in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6583324" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Cranial nerve involvement in children with leukemia and lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2407298" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Open-wedge testicular biopsy in childhood acute lymphoblastic leukemia after two years of maintenance therapy: diagnostic accuracy and influence on outcome--a report from Children's Cancer Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11333138" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The detection and significance of chromosomal abnormalities in childhood acute lymphoblastic leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15877734" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
